Kitov Pharmaceuticals Holdings, Zock oder mehr?
26.06.20 08:16
#101
Nervous
Tel Aviv
hat heute die Börse zu...
also keine News, aber man munkelt viel, dass hier mit MERCK kooperiert wird...
mal sehen was da nächste Woche auf uns zukommt! sehr spannend!
also keine News, aber man munkelt viel, dass hier mit MERCK kooperiert wird...
mal sehen was da nächste Woche auf uns zukommt! sehr spannend!
26.06.20 10:15
#102
Küstennebel
Moin Nervous
Wo munkelt man denn? Auf Stocktwits? Sollte das so sein, wäre ich vorsichtig. Denk an die RobinHood Trader...!
26.06.20 10:30
#103
Nervous
richtig ja...
aber colab steht auf jeden Fall an, ist auch in der Pipeline...
somit sollte am Preis noch was passieren,
offering wurde gestern geschlossen.
mal sehen wie es weitergeht.
somit sollte am Preis noch was passieren,
offering wurde gestern geschlossen.
mal sehen wie es weitergeht.
01.07.20 12:26
#104
Vassago
KTOV 0.97$ (vorbörslich -13%)
35 Mio. $ Offering
- 38,9 Mio. ADS´s zu je 0,90$ = ~35 Mio. $
http://kitovpharma.investorroom.com/news-releases?item=107
04.08.20 12:20
#108
larsuwe
Mal schauen, wo wir am Fr.stehen werden
Kitov Pharmaceuticals bekommt immer mehr Aufmerksamkeit !.
22.03.21 11:13
#110
dyesbis
es geht voran ...
es geht voran
https://www.globenewswire.com/news-release/2021/...anced-Cancers.html
https://www.globenewswire.com/news-release/2021/...anced-Cancers.html
01.04.21 07:37
#111
Blauschwert
nächste Woche
Präsentation zu Phase III mit anschließender Telefonkonferenz für Analysten. Momentum sollte nächste Woche anziehen.
01.04.21 08:57
#112
dyesbis
Danke für die Info!
Danke für die Info!
die sind ja noch in Phase I/II mit CM24 und NT219
mehr als das Studiendesign von Phase III wird da nicht kommen, oder?
eventuell ein paar (erfreuliche) Zwischenergebnisse aus den frühen Phasen
die sind ja noch in Phase I/II mit CM24 und NT219
mehr als das Studiendesign von Phase III wird da nicht kommen, oder?
eventuell ein paar (erfreuliche) Zwischenergebnisse aus den frühen Phasen
01.04.21 09:02
#113
dyesbis
Reden wir ...
Reden wir bei der Präsentation von der Präsentation auf dem American Association of Cancer Research (AACR) 2021 Annual Meeting oder ist da was anderes auch noch geplant?
10.04.21 10:53
#114
Blauschwert
Konferenz
zu den Studienergebnissen zu einem der Medikamente beginnt heute
13.04.21 19:51
#115
Blauschwert
Veröffentlichung
13.04.2021
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, were presented in a poster entitled "Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2," at the American Association of Cancer Research (AACR) 2021 Annual Meeting. These data update and expand on the results previously reported by the Company from its collaboration with Professor Ido Wolf, Head of the Oncology Division at Tel Aviv Sourasky Medical Center.
Colorectal cancer (CRC) represents the fourth most frequent cause of brain metastasis, which is the most common brain tumor. The study included an analysis of more than 16,000 human CRC local and metastasis samples, and revealed increased amplification of IRS2 in brain metastases.
In an in vitro system mimicking the brain microenvironment, IRS2-overexpressed CRC cells showed prolonged survival. Importantly, transcriptomic analysis demonstrated significant enrichment of the oxidative phosphorylation (OXPHOS) pathway by IRS2. CRC cells expressing IRS2 showed increased mitochondrial activity and glycolysis-independent viability. Inhibition of IRS2 using NT219 dose-dependently inhibited IRS2-expressing cells viability and OXPHOS genes expression.
The Wnt/β-catenin pathway was among the most significantly enriched pathways in the brain metastasis, as IRS2-expressing cells showed increased transcriptional activity of the β-catenin. In addition, NT219 decreased the transcriptional activity of β-catenin in IRS2-expressing CRC cells to a greater extent than AKT and PI3K inhibitors, and most significantly suggested relevance of IRS2 in activating β-catenin. It was further shown that 5-FU, a chemotherapy approved for treating CRC, elevated β-catenin expression, and that NT219 diminished both 5FU-induced and the basal level of the β-catenin expression. Utilizing an intracranial animal model, it was also demonstrated that while 5-FU alone had no significant effect, the combination of 5-FU and NT219 significantly inhibited the formation of brain metastasis and extended survival rates of the study mice.
"We are excited about these highly encouraging study results," said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. "These compelling data provide important insights regarding the role of IRS2 in promoting CRC brain metastasis, and suggest that novel agents such as NT219 have the potential to effectively inhibit the development of brain metastasis. Our ongoing Phase 1/2 clinical trial of NT219 as monotherapy for the treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer, is proceeding with enrollment as planned and we continue to expect the availability of top-line data from the first part of this study in the second half of this year."
The poster presentation is available at https://purple-biotech.com/2021/04/12/...irtual-meeting-poster-2021/.
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, were presented in a poster entitled "Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2," at the American Association of Cancer Research (AACR) 2021 Annual Meeting. These data update and expand on the results previously reported by the Company from its collaboration with Professor Ido Wolf, Head of the Oncology Division at Tel Aviv Sourasky Medical Center.
Colorectal cancer (CRC) represents the fourth most frequent cause of brain metastasis, which is the most common brain tumor. The study included an analysis of more than 16,000 human CRC local and metastasis samples, and revealed increased amplification of IRS2 in brain metastases.
In an in vitro system mimicking the brain microenvironment, IRS2-overexpressed CRC cells showed prolonged survival. Importantly, transcriptomic analysis demonstrated significant enrichment of the oxidative phosphorylation (OXPHOS) pathway by IRS2. CRC cells expressing IRS2 showed increased mitochondrial activity and glycolysis-independent viability. Inhibition of IRS2 using NT219 dose-dependently inhibited IRS2-expressing cells viability and OXPHOS genes expression.
The Wnt/β-catenin pathway was among the most significantly enriched pathways in the brain metastasis, as IRS2-expressing cells showed increased transcriptional activity of the β-catenin. In addition, NT219 decreased the transcriptional activity of β-catenin in IRS2-expressing CRC cells to a greater extent than AKT and PI3K inhibitors, and most significantly suggested relevance of IRS2 in activating β-catenin. It was further shown that 5-FU, a chemotherapy approved for treating CRC, elevated β-catenin expression, and that NT219 diminished both 5FU-induced and the basal level of the β-catenin expression. Utilizing an intracranial animal model, it was also demonstrated that while 5-FU alone had no significant effect, the combination of 5-FU and NT219 significantly inhibited the formation of brain metastasis and extended survival rates of the study mice.
"We are excited about these highly encouraging study results," said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. "These compelling data provide important insights regarding the role of IRS2 in promoting CRC brain metastasis, and suggest that novel agents such as NT219 have the potential to effectively inhibit the development of brain metastasis. Our ongoing Phase 1/2 clinical trial of NT219 as monotherapy for the treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer, is proceeding with enrollment as planned and we continue to expect the availability of top-line data from the first part of this study in the second half of this year."
The poster presentation is available at https://purple-biotech.com/2021/04/12/...irtual-meeting-poster-2021/.
14.04.21 07:45
#116
dyesbis
nicht so viel ...
nicht so viel wie erhofft, aber dass die spannenden Zahlen erst in ein paar Monaten kommen, war schon lange klar
wir warten also weiter. wirklich spannend wird dann das Ergebnis der Kombination aus NT219 und cetuximab
und CM24 gibt es ja auch noch :D
wir warten also weiter. wirklich spannend wird dann das Ergebnis der Kombination aus NT219 und cetuximab
und CM24 gibt es ja auch noch :D
26.04.21 08:29
#117
dyesbis
und wieder ein kleines Update
https://www.globenewswire.com/news-release/2021/...ncer-Patients.html
20.05.21 13:06
#118
Blauschwert
neue Veröffentlichung
https://www.pressviewer.com/...amp;p=2195304&I=1270120-b3h8I2r8t4
21.05.21 07:49
#119
dyesbis
wenn NT219 ...
wenn NT219 bei Menschen nur ein Bruchteil so gut funktioniert wie in den Tests im Labor, dann bin ich ein sehr glücklicher Mann
28.05.21 11:15
#120
Blauschwert
Präsentation announced
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
REHOVOT, Israel, May 26, 2021 -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 8:30am EST. The conference will take place from June 1 - June 4, 2021. Management will be available for one-on-one meetings.
Jefferies Virtual Healthcare Conference - June 1-4, 2021
Date: Friday, June 4, 2021
Time: 8:30-8:55am EST
REHOVOT, Israel, May 26, 2021 -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 8:30am EST. The conference will take place from June 1 - June 4, 2021. Management will be available for one-on-one meetings.
Jefferies Virtual Healthcare Conference - June 1-4, 2021
Date: Friday, June 4, 2021
Time: 8:30-8:55am EST
28.05.21 14:05
#121
dyesbis
spannenderweise ...
spannenderweise beides an einem Tag
zuerst die Jefferies Virtual Healthcare Conference und später am gleichen Tag werden die ersten Daten von NT219 aus Tests an Menschen präsentiert
die FOMO ist auch schon recht stark
heute hab ich schon 5,50 Dollar premarket gesehen
zuerst die Jefferies Virtual Healthcare Conference und später am gleichen Tag werden die ersten Daten von NT219 aus Tests an Menschen präsentiert
die FOMO ist auch schon recht stark
heute hab ich schon 5,50 Dollar premarket gesehen
28.05.21 14:54
#122
Blauschwert
lohnenswerter Termin
So scheint es hoffentlich. wären die nicht verpflichtet schlechte Ergebnisse per adhoc Mitteilung zu veröffentlichen?
01.06.21 12:31
#123
dyesbis
keine Ahnung ...
... hab beim israelischen Aktienrecht in der Schule leider gefehlt :D
aber die Tatsache, dass sie es auf der ASCO präsentieren deutet auf eher brauchbare Ergebnisse hin
aber die Tatsache, dass sie es auf der ASCO präsentieren deutet auf eher brauchbare Ergebnisse hin
04.06.21 12:35
#124
Kicky
Rankings Purple Biotech ADR
https://stocktwits.com/rankings PPBT steigt heute 12,6 % bei Tradegate
04.06.21 15:43
#125
Kicky
Purple Biotech new clinical data from NT2 at Asco
https://seekingalpha.com/news/...ta-from-nt219-at-asco-annual-meeting